Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
Sustainability shifts that will define 2026
BY THE OPTIMIST DAILY EDITORIAL TEAM Sustainability is no longer a distant future goal; it’s a present-day responsibility. As we move into 2026, environmental ...
Read MoreHouse burping explained: the surprisingly simple habit that could make your h...
BY THE OPTIMIST DAILY EDITORIAL TEAM If you’ve seen people dramatically flinging open their windows on social media lately, declaring it’s time to “burp ...
Read MoreScientists are battling locust swarms from space
Locust swarms are serious. In a single day, a desert locust swarm (about 40 million bugs) can eat as much food as 35,000 people in a ...
Read MoreUnleashing the power of joy lists
In their quest to break away from life's monotony, many people have discovered the transforming concept of a pleasure list. The joy list is ...
Read More
